GLCCI1-DT: A Drug Target / Disease Biomarker (G100505921)

Target Name: GLCCI1-DT

NCBI ID: G100505921

GLCCI1-DT

Other Name(s): GLCCI1 divergent transcript

GLCCI1-DT: A Drug Target / Disease Biomarker

GLCCI1-DT is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The GLCCI1 gene encodes for a protein that is characterized by a unique molecular domain that is composed of a long alpha-helices and a short beta-sheet.

The alpha-helices are responsible for the protein's stability and can be involved in the formation of helices that interact with other proteins. The beta-sheet is a structural unit that is responsible for the protein's stability and can be involved in the formation of beta-helices.

GLCCI1-DT has been shown to be involved in the development and progression of neurodegenerative diseases by interacting with the protein Parkin, which is a protein that is known to play a role in the development and progression of neurodegenerative diseases.

Parkin is a protein that is characterized by a unique molecular domain that is composed of a long alpha-helices and a short beta-sheet. The alpha-helices are responsible for the protein's stability and can be involved in the formation of helices that interact with other proteins. The beta-sheet is a structural unit that is responsible for the protein's stability and can be involved in the formation of beta-helices.

GLCCI1-DT has been shown to interact with Parkin by forming a complex with the protein. This complex plays a role in the development and progression of neurodegenerative diseases by promoting the growth and survival of neurodegenerate cells.

In conclusion, GLCCI1-DT is a protein that is characterized by a unique molecular domain that is composed of a long alpha-helices and a short beta-sheet. The alpha-helices are responsible for the protein's stability and can be involved in the formation of helices that interact with other proteins. The beta-sheet is a structural unit that is responsible for the protein's stability and can be involved in the formation of beta-helices. GLCCI1-DT has been shown to interact with Parkin by forming a complex with the protein. This complex plays a role in the development and progression of neurodegenerative diseases by promoting the growth and survival of neurodegenerate cells. Further research is needed to fully understand the role of GLCCI1-DT as a drug target or biomarker for the development and progression of neurodegenerative diseases.

Protein Name: GLCCI1 Divergent Transcript

The "GLCCI1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLCCI1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets